PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25725071-5	2015	In human hepatocytes, treatment of GW4064 (1 muM) for 48 hours resulted in a 75% decrease in CYP3A4 mRNA expression and a 25% decrease in CYP3A4 activity, accompanied by ~3-fold increase in SHP mRNA expression.	GW 4064	35-41	nuclear receptor subfamily 0 group B member 2	Homo sapiens	190-193	
25725071-8	2015	In conclusion, GW4064 represses CYP3A4 expression in human hepatocytes, potentially through upregulation of SHP expression and subsequent repression of CYP3A4 promoter activity.	GW 4064	15-21	nuclear receptor subfamily 0 group B member 2	Homo sapiens	108-111	
22800197-11	2012	In LS174T/R cells, GW4064 induced the expression of FGF19, SHP, OSTalpha/beta, but not MRP2 and BCRP, although the sensitivity of these cells to cisplatin was further reduced.	GW 4064	19-25	nuclear receptor subfamily 0 group B member 2	Homo sapiens	59-62	
23313557-7	2013	In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OSTbeta, and a down-regulation of CYP27A1.	GW 4064	66-72	nuclear receptor subfamily 0 group B member 2	Homo sapiens	97-100	
18029909-4	2007	METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid.	GW 4064	163-169	nuclear receptor subfamily 0 group B member 2	Homo sapiens	42-67	
18029909-4	2007	METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid.	GW 4064	163-169	nuclear receptor subfamily 0 group B member 2	Homo sapiens	69-72	
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 0 group B member 2	Homo sapiens	140-165	
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 0 group B member 2	Homo sapiens	167-170	
17047076-6	2006	At lower concentrations that had no direct effect on viability, the FXR agonist GW4064 induced expression of mRNA for the FXR target genes, small heterodimer partner (SHP), intestinal bile acid binding protein, and multidrug resistance-associated protein 2 (MRP-2), and repressed the expression of the SHP target gene aromatase.	GW 4064	80-86	nuclear receptor subfamily 0 group B member 2	Homo sapiens	302-305	
15817812-5	2005	In addition, ICAM-1 and SHP mRNA levels were also induced in primary human hepatocytes when treated with chenodeoxycholic acid or GW4064, a FXR-selective agonist.	GW 4064	130-136	nuclear receptor subfamily 0 group B member 2	Homo sapiens	24-27	
15817812-7	2005	Both ICAM-1 and SHP expression were induced in a dose- and time-dependent manner by treatment with the FXR-selective agonist GW4064.	GW 4064	125-131	nuclear receptor subfamily 0 group B member 2	Homo sapiens	16-19